Related Experiment Videos
Formatting antibody fragments to mediate specific therapeutic functions
A N C Weir1, A Nesbitt, A P Chapman
1Celltech R+D Ltd., 216 Bath Road, Slough, Berkshire SL1 4EN, UK. neil.weir@slh.celltechgroup.com
Biochemical Society Transactions
|August 28, 2002
Summary
Therapeutic monoclonal antibodies utilize antigen specificity for various treatments. Fab fragments offer versatile mechanisms of action and manufacturing advantages over traditional antibody structures.
Area of Science:
- Biotechnology
- Immunology
- Pharmacology
Background:
- Monoclonal antibodies are widely used therapeutics targeting specific antigens in oncology, inflammation, and infectious diseases.
- Their therapeutic efficacy relies on high specificity and affinity for target antigens.
- The precise mechanism of action (MOA) varies significantly between different antibody-based drugs.
Purpose of the Study:
- To explore the diverse mechanisms of action for monoclonal antibodies.
- To evaluate the potential of antibody fragments, specifically Fab fragments, in therapeutic applications.
- To address manufacturing challenges associated with traditional antibody structures.
Main Methods:
- Categorization of antibody mechanisms of action into antagonists, agonists, and targeted delivery systems.
- Analysis of the structural requirements for different MOAs, including the role of the Fc region.
- Evaluation of Fab fragment engineering for controlled valency, half-life, and simplified drug design.
- Consideration of microbial expression systems for Fab fragment production.
Main Results:
- Monoclonal antibodies employ diverse MOAs, including antagonism, agonism, and targeted delivery (e.g., cell killing, effector cell recruitment, drug delivery).
- While Fc-mediated functions (e.g., ADCC, complement lysis) require the Fc region, Fab fragments can be engineered to mediate most MOAs.
- Fab fragments offer advantages in controlling valency and half-life, simplifying drug design.
- Microbial expression systems present a viable option for scalable and cost-effective production of Fab fragments.
Conclusions:
- Fab fragments represent a flexible and advantageous alternative to full-length monoclonal antibodies for various therapeutic applications.
- Engineering Fab fragments allows for tailored therapeutic strategies and improved manufacturing processes.
- The development of antibody fragment-based therapeutics holds significant promise for addressing unmet medical needs and reducing production costs.